Mechanistic Investigation and Implications of Photodynamic Therapy Induction of Vascular Endothelial Growth Factor in Prostate Cancer
Open Access
- 1 June 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (11), 5633-5640
- https://doi.org/10.1158/0008-5472.can-06-0604
Abstract
Photodynamic therapy (PDT) is now an approved therapeutic modality, and induction of vascular endothelial growth factor (VEGF) following subcurative PDT is of concern as VEGF may provide a survival stimulus to tumors. The processes that limit the efficacy of PDT warrant investigation so that mechanism-based interventions may be developed. This study investigates VEGF increase following subcurative PDT using the photosensitizer benzoporphyrin derivative (BPD) both in an in vitro and in an orthotopic model of prostate cancer using the human prostate cancer cell line LNCaP. The two subcurative doses used, 0.25 and 0.5 J/cm2, mimicked subcurative PDT and elicited a 1.6- and 2.1-fold increase, respectively, in secreted VEGF 24 hours following PDT. Intracellular VEGF protein measurement and VEGF mRNA showed a 1.4- and 1.6-fold increase only at 0.5 J/cm2. In vivo subcurative PDT showed an increase in VEGF by both immunohistochemistry and ELISA. In vitro analysis showed no activation of hypoxia-inducible factor-1α (HIF-1α) or cyclooxygenase-2 (COX-2) following subcurative PDT; furthermore, small interfering RNA inhibition of HIF-1α and COX-2 inhibitor treatment had no effect on PDT induction of VEGF. PDT in the presence of phosphatidylinositol 3-kinase/AKT inhibitor or mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase inhibitor still induced VEGF. However, subcurative PDT increased phosphorylated p38 and stress-activated protein kinase/c-Jun NH2-terminal kinase. The p38 MAPK inhibitor abolished PDT induction of VEGF. The results establish the importance of VEGF in subcurative BPD-PDT of prostate cancer and suggest possible molecular pathways for its induction. These findings should provide the basis for the development of molecular-based interventions for enhancing PDT and merit further studies. (Cancer Res 2006; 66(11):5633-40)Keywords
This publication has 36 references indexed in Scilit:
- Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic ImplicationsClinical Cancer Research, 2006
- Celecoxib and NS-398 Enhance Photodynamic Therapy by Increasing In vitro Apoptosis and Decreasing In vivo Inflammatory and Angiogenic FactorsCancer Research, 2005
- Photodynamic Therapy for Prostate Cancer Recurrence After Radiotherapy: A Phase I StudyJournal of Urology, 2002
- VEGF isoforms and mutations in human colorectal cancerInternational Journal of Cancer, 2002
- Stabilization of Vascular Endothelial Growth Factor mRNA by Hypoxia-Inducible Factor 1Biochemical and Biophysical Research Communications, 2002
- MTT assays allow quick and reliable measurement of the response of human tumour cells to photodynamic therapyEuropean Journal of Cancer, 1992
- Photodynamic therapyEuropean Journal of Cancer, 1992
- Metastatic Model for Human Prostate Cancer Using Orthotopic Implantation in Nude MiceJNCI Journal of the National Cancer Institute, 1992
- Plasma membrane depolarization and calcium influx during cell injury by photodynamic actionBiochimica et Biophysica Acta (BBA) - Biomembranes, 1991
- Photodynamic therapy of localised prostatic cancerThe Lancet, 1990